Kezar Life Sciences, Inc. (KZR)

Market Cap	57.51M
Revenue (ttm)	7.00M
Net Income (ttm)	-101.87M
Shares Out	72.80M
EPS (ttm)	-1.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416,536
Open	0.780
Previous Close	0.788
Day's Range	0.771 - 0.804
52-Week Range	0.670 - 3.130
Beta	0.46
Analysts	Buy
Price Target	11.00 (+1,292.41%)
Earnings Date	May 9, 2024

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR

Analyst Forecast

According to 3 analysts, the average rating for KZR stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 1,292.41% from the latest price.

Price Target

$11.0

(1,292.41% upside)

Analyst Consensus: Buy